4SC AG — Capital/Financing Update 2008

Jul 14, 2008

News Details

Ad-hoc | 14 July 2008 15:57

Capital Increase and complete Placement of new 4SC AG Shares

4SC AG / Capital Increase

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Planegg-Martinsried, Germany, 14 July 2008 – The Martinsried-based drug
discovery and development company 4SC AG (Frankfurt, Prime Standard: VSC)
announces the placement of new shares, after the Management Board, with the
approval of the Supervisory Board, passed a resolution to authorise an
increase of share capital on 20 June 2008. The capital increase from the
authorised capital included a collateral rights offering to existing
shareholders at a subscription price of 3.10 Euro per share. The remaining
unsubscribed shares were completely used for a private placement at the
subscription price. The capital increase generated approx. 29.45 million
Euros in gross proceeds for the company.

The proceeds of the capital increase are to be used for financing the
acquisition of Nycomed's oncology projects in the amount of 14 million
Euros. Additional funds are to be used for further development of the
existing as well as the new project pipeline of 4SC AG. The corporate
action was supported by Santo Holding (Deutschland) GmbH, who is the
largest single shareholder in 4SC AG.

Following the completion of the capital increase, a total of 9,500,913 new
shares were placed. As a result of the capital increase, 4SC AG's
subscribed capital increased to 28,502,739.00 Euros. The free float is
approximately 29.24 percent of issued shares based on today’s knowledge.
The approval of the new shares for trading at the Frankfurt Stock Exchange
is not expected before November / December 2008.

The capital increase was accompanied by Conrad Hinrich Donner Bank AG.

---

Information and Explaination of the Issuer to this News:

About 4SC AG:
4SC AG (ISIN DE0005753818) has been listed in the Prime Standard of
Frankfurt Stock Exchange since 15 December 2005. Founded in 1997 and now
with a staff of 74, the company develops novel drug candidates for
inflammatory diseases, cancer and infectious diseases.
4SC AG utilises its technology platform, which is protected by patent, to
create a sustainable project pipeline of drug candidates, which are to be
developed up to proof of clinical efficacy in early clinical phases ('proof
of concept') and subsequently licensed to the pharmaceutical industry in
return for advance and milestone payments as well as royalties.

There are currently six projects in the pipeline and a so-called ideas’
pool with further development candidates. In addition the pipeline will be
completed by the acquired Nycomed projects. The first project for the
treatment of rheumatoid arthritis has already successfully completed
clinical phase IIa. Further projects are in advanced pre-clinical and have
the potential to reach clinical maturity at short notice. Beside own
product development 4SC AG is implementing its technology platform in
collaborations with pharmaceutical and biotechnology companies.

Further information is to be found at www.4sc.com

Legal Note
This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.

For more information please contact:
Bettina von Klitzing
Manager Investor Relations & Public Relations
4SC AG
Tel.: +49 (0) 89 70 07 63 - 0
Bettina.von.Klitzing@4sc.com

14.07.2008 Financial News transmitted by DGAP

Language: English
Issuer: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Deutschland
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public@4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart

End of News DGAP News-Service

---